

Gradient Method Scaling for Life Cycle Management of a USP Impurities Method

Amanda B. Dlugasch, Jennifer Simeone, and Patricia R. McConville
 Waters Corporation, Milford, MA, USA

APPLICATION BENEFITS

- The Waters™ Columns Calculator enables users to geometrically scale methods
- Improved throughput is obtained by scaling HPLC columns to those with smaller particle sizes and shorter column lengths
- The quetiapine fumarate impurities method run time was reduced by 51% using a 2.5 μm column with a UHPLC system and 75% using a 1.7 μm column with a UPLC™ system
- Equivalent chromatographic and quantitative performance was achieved for the quetiapine fumarate impurities method across all separations

WATERS SOLUTIONS

[Alliance™ HPLC System](#)

[ACQUITY™ Arc™ UHPLC System](#)

[ACQUITY UPLC H-Class PLUS System](#)

[Waters Columns Calculator](#)

[XBridge™ Columns](#)

[ACQUITY UPLC Columns](#)

[Empower™ 3 Chromatography Data Software](#)

KEYWORDS

Quetiapine fumarate, column scaling, method modernization, dwell volume, USP, life cycle management

INTRODUCTION

Pharmaceutical companies often follow compendial high performance liquid chromatography (HPLC) methods for the analysis of raw materials and finished products. However, modernization of older HPLC methods, which can include scaling or transfer¹ of a method to new column or LC technologies should be considered as part of pharmaceutical lifecycle management.² The successful scaling of a method requires the proper adjustment of various method parameters including column particle size and dimension, flow rate, injection volume, and gradient timing.

In this study, the USP impurity monograph for quetiapine fumarate³ will be scaled to smaller particle sized columns using the Waters Columns Calculator. The scaled methods will then be compared to the original HPLC method to ensure no loss of chromatographic or quantitative performance. The scaled methods provide decreased run times and solvent consumption while providing equivalent chromatographic performance.




Figure 1. Chemical structures of quetiapine fumarate, and its impurities, quetiapine related compound B, quetiapine related compound G, and quetiapine desethoxy.

EXPERIMENTAL

Sample description

The quetiapine fumarate standard (catalog#: 1592704), and the quetiapine system suitability standard (catalog#: 1592715) were purchased from the United States Pharmacopeia. The unknown quetiapine fumarate sample was purchased from Alibaba.com.

All solutions were prepared to the designated concentrations per the USP monograph. The system suitability and the standard solutions were prepared in the diluent comprised of Solution A: Solution B (86:14). The unknown sample solution was prepared in Solution A.

The concentrations of the solutions are 1.0 mg/mL for the system suitability solution, 0.001 mg/mL for the standard solution, and 1.0 mg/mL for the unknown sample solution.

Method conditions

Mobile phase: Solution A:
Acetonitrile and buffer (25:75)
Solution B: Acetonitrile

Buffer: 3.1 g/L of ammonium acetate in water.
2 mL of 25% ammonium hydroxide was added to each 1 liter of solution.
The final pH is not less than (NLT) 9.2

PDA wavelength: 250 nm at 4.8 nm resolution

Gradient table:

Instrument gradient time			Gradient composition	
HPLC (min)	UHPLC (min)	UPLC (min)	Solution A (%)	Solution B (%)
0.0	0.0	0.0	100	0.0
25.0	11.90	6.07	100	0.0
60.0	28.57	14.57	29.3	70.7
60.1	28.62	14.6	100	0.0
68.0	32.38	16.51	100	0.0
70.0	34.0	17.00	100	0.0

LC systems and conditions

HPLC system: Alliance e2695 Separations Module with 100 µL syringe, 2998 PDA Detector and CH-30 equipped with the passive column preheater

Column: XBridge BEH C₈, 3.5 µm, 4.6 mm × 150 mm (p/n: [186003055](#))

Sample temp.: 4 °C

Column temp.: 45 °C

Injection volume: 20.0 µL

Flow rate: 1.500 mL/min

Pre-injection volume: NA

Run time: 70 minutes

UHPLC system: ACQUITY Arc (path 2) with active solvent preheating (CH-30A) and 2998 PDA Detector

Column: XBridge BEH C₈ XP, 2.5 µm, 3.0 mm × 100 mm (p/n: [186006047](#))

Sample temp.: 4 °C

Column temp.: 45 °C

Injection volume: 5.7 µL

Flow rate: 0.893 mL/min

Pre-injection volume: 388 µL

Run time: 34 minutes

UPLC system: ACQUITY UPLC H-Class PLUS with active solvent preheating (CH-30A), 50 µL extension loop and ACQUITY UPLC PDA Detector

Column: ACQUITY UPLC BEH C₈, 1.7 µm, 2.1 mm × 75 mm (p/n: [186005606](#))

Sample temp.: 4 °C

Column temp.: 45 °C

Injection volume: 2.1 µL

Flow rate: 0.644 mL/min

Pre-injection volume: 285 µL

Run time: 17 minutes

Data management

Empower 3 Chromatography Data Software, FR 4

RESULTS AND DISCUSSION

METHODOLOGY

The quetiapine fumarate impurities USP method was first analyzed on the Alliance HPLC System using the described monograph conditions.³ Performance was evaluated based on the system suitability requirements as outlined in the monograph, which include resolution, tailing, and RSD for peak retention time and area. The column dimensions and method conditions were then geometrically scaled to columns with smaller particles.⁴

The first step in method scaling is to select the column dimensions and particle size. The column selected should maintain the L/dp ratio, where L is the length of the column and dp is the diameter of the particle size. The L/dp ratio is critical to maintain the resolving power of the column.⁵

Once the appropriate column length and particle size are determined, the adjusted flow rate can be calculated. This ensures the same linear velocity is maintained from the original method to the scaled method. The modified flow rate is based on the internal diameter of the columns, the particle size of the columns, and the original flow rate using the following equation:

$$F_2 = F_1 \times (dp_1/dc_1) / (dp_2/dc_2)$$

where F_1 and F_2 are the flow rates (mL/min) for the original and scaled method, respectively; dp_1 and dp_2 are the diameters of the particle sizes (μm) of the original and scaled methods, respectively, and dc_1 and dc_2 are the column diameters (mm) for the original and scaled method, respectively.⁶

In scaling methods, it is also important to adjust the injection volume to maintain sensitivity, linearity, etc. Thus, the injection volume needs to be adjusted with column volumes using the following equation:

$$V_{inj2} = V_{inj1} \times (V_{02}/V_{01})$$

where V_{inj1} and V_{inj2} are the injection volumes for the original and scaled methods, respectively, and V_{01} and V_{02} are the column void volumes for the original and scaled methods, respectively.⁶

To maintain the separation, the gradient step must be kept constant in terms of column volumes. To do this, the column volumes must be calculated for the original method and then preserved for the scaled method. The number of column volumes determined for each segment is calculated as follows:

$$CV = (F \times T) / V_0$$

where CV is equal to column volumes, F is the flow rate (mL/min), T is the segment duration (minutes), and V_0 is the column void volume (mL).⁶ Since the void volume and flow rate are constant, the time duration of each gradient step in the scaled method can be calculated based on the required column volume.

Geometrically scaling a gradient method can seem challenging, but there is a tool to assist users in completing all of the necessary method adjustments.⁷ The Waters Columns Calculator determines the flow rate, the injection volume, as well as the timing for each gradient step. Once a user enters in the required information (column dimensions, particle size, original method gradient table, etc.) the scaled method conditions are automatically calculated. (Figure 2 and Figure 3).

In order to preserve the original HPLC column L/dp ratio the column dimensions and particle size were scaled to a UHPLC column with a 2.5 μm particle size and 3.0 mm \times 100 mm column dimensions. The UHPLC column L/dp ratio decreased by 7% from the HPLC column. The Waters Columns Calculator (Figure 2) scaled the flow rate to 0.893 mL/min and the injection volume to 5.7 μL for the UHPLC method.

The Waters Columns Calculator was also used to scale the quetiapine fumarate impurity method to a UPLC column with 1.7 μm particle size and 2.1 mm \times 75 mm dimensions (Figure 3). The scaled column dimensions resulted in an L/dp ratio increase of 3%, a flow rate of 0.644 mL/min and the injection volume of 2.1 μL .

The dwell volume, or gradient delay volume, is the volume between the point of solvent mixing and the head of the column. Since the dwell volume is effectively an isocratic hold at the beginning of a gradient, it can affect selectivity, resolution, and retention in method scaling. Therefore, when scaling methods, the dwell volume is often kept constant in terms of column volumes. In fact, this is part of the method scaling parameters determined using the Waters Columns Calculator.

To account for the dwell volume differences, the values for the two LC systems were determined⁸ and entered into the Waters Columns Calculator. The dwell volume in terms of column volume varied for the Alliance HPLC System, the ACQUITY UHPLC Arc System, and the ACQUITY UPLC H-Class PLUS System. Thus, when scaling from the Alliance HPLC System (and column), "pre-injection volumes" were required for both the UHPLC scaled method (388 μL) and the UPLC method (285 μL).




Figure 2. Waters Columns Calculator. HPLC method conditions calculated to UHPLC method conditions.




Figure 3. Waters Columns Calculator. HPLC method conditions calculated to UPLC method conditions.

SCALING OF A GRADIENT METHOD FROM HPLC TO UHPLC AND UPLC

To evaluate the performance of the scaled methods, the results were compared to the original HPLC method run on the Alliance HPLC System. Additionally, an unknown sample was analyzed on each of the three systems to determine the quantitative reproducibility of the scaled methods.

The original HPLC method as well as the two scaled methods all show similar chromatographic performance (Table 1) in terms of resolution, tailing, and peak area and retention time RSDs. Chromatograms of the system suitability solution and the unknown sample solution are shown in Figure 4 and 5, respectively.

Table 1. Comparison of the results obtained on the Alliance HPLC System, the ACQUITY Arc UHPLC System, and the ACQUITY UPLC H-Class PLUS Systems. Also included is the run time and solvent consumption for each method.

	Resolution (peak 1 and 2)	Resolution (peak 3 and 4)	Quetiapine tailing	Quetiapine area %RSD	Quetiapine retention time %RSD	Run time (min)	Solvent consumption per sample (mL)
Alliance HPLC	14.0	7.0	1.03	1.24	0.04	70	105
ACQUITY Arc UHPLC	13.2	6.7	0.95	0.57	0.02	34	30
ACQUITY UPLC H-Class PLUS	11.2	5.4	1.04	0.65	0.02	17	11

Scaling the original HPLC method to a smaller particle column significantly decreased the run time and solvent consumption. Scaling the original method to a 2.5 μm column decreased the run time from 70 minutes to 34 minutes (51%), and decreased the solvent usage by 71%. Further scaling the method to a 1.7 μm column was able to decrease the run time from 70 minutes to 17 minutes (75%) and reduce the solvent usage by 89%.

To evaluate the quantitative reproducibility of the methods, an unknown sample was analyzed. The standard solution and the unknown sample solution data were used to calculate the percent of impurity for each peak in the unknown sample as follows:

$$\text{Result} = (r_u/r_s) \times (C_s/C_u) \times (1/F) \times 100$$

where r_u is the peak response of each impurity from the sample solution, r_s is the peak response of quetiapine from the standard solution, C_s is the concentration of USP quetiapine fumarate standard in the standard solution (mg/mL), C_u is the concentration of quetiapine fumarate in the sample solution (mg/mL) and F is the relative response factor for the impurity peak provided in the monograph.³




Figure 4. Quetiapine fumarate system suitability solution run on the Alliance HPLC System (3.5 μm particle column), the ACQUITY Arc UHPLC System (2.5 μm particle column), and the ACQUITY UPLC H-Class PLUS System (1.7 μm particle column). Peak identification: 1: quetiapine related compound G, 2: quetiapine related compound B, 3: quetiapine desethoxy, and 4: quetiapine.




Figure 5. Comparison of the unknown sample solution analyzed on the Alliance HPLC System (3.5 μm particle column), the ACQUITY Arc UHPLC System (2.5 μm particle column), and the ACQUITY UPLC H-Class PLUS System (1.7 μm particle column). Peak identification: 1: quetiapine desethoxy, 2: quetiapine, and 3: unknown impurity.

Two impurity peaks were found in the unknown sample, quetiapine desethoxy and an unknown impurity. The calculated percent for each impurity as well as the total amount of impurities in the unknown sample can be found in Table 2. All methods provided equivalent impurity amounts for the unknown sample.

Table 2. Calculated impurity results obtained for all three methods on the three different LC systems.

Unknown sample	Quetiapine desethoxy	Unknown impurity	Total impurities
Alliance HPLC System	0.12%	0.08%	0.22%
ACQUITY Arc UHPLC System	0.09%	0.06%	0.17%
ACQUITY UPLC H-Class PLUS System	0.10%	0.07%	0.19%

Whenever a method is adjusted, producing consistent reliable results is a critical factor. Scaling the USP quetiapine fumarate impurities method across the different LC systems produced equivalent quantification of impurities contained within a sample of API.

CONCLUSIONS

It is possible to scale traditional HPLC methods to columns with a smaller particle size in order to significantly decrease run time and solvent consumption while still providing the same chromatographic and quantitative performance. This was demonstrated by scaling a USP monograph which uses a gradient elution using the Waters Columns Calculator. The scaled method conditions reduced the original run time by 51% for the 2.5 μm column and 75% for the 1.7 μm column. The scaled methods maintained similar chromatographic performance in terms of resolution, peak tailing, and retention time and peak area RSD. Additionally, quantitative results for impurities contained in the API sample were consistent regardless of which method was used.

References

1. Fountain, Kenneth. Transferring Compendial HPLC Methods to UPLC Technology for Routine Generic Drug Analysis. Application Note. [720004251en](#), 2012.
2. Guidance for Industry Q10 Pharmaceutical Quality System. ICH, 2008.
3. Official Monographs, Quetiapine Fumarate USP 40 NF35 S1, United States Pharmacopeia and National Formulary (USP 40-NF35 S1) Baltimore, MD: United Book Press, Inc.; 2017. p. 5939.
4. Neue Uwe D., McCabe, Doug, Ramesh, Vijaya, Pappa, Horacio, DeMuth Jim. Transfer of HPLC Procedures to Suitable Columns of Reduced Dimensions. *Pharmaceutical Forum* 2009 Nov–Dec; 35(6):1622.
5. Swann, Thomas. Nguyen, Jennifer M. USP Method Modernization Using “Equivalent L/dp” and “Equivalent N” Allowed Changes with CORTECS C₈ and CORTECS C₈ Columns. Application Note. [720005666en](#), 2016.
6. Columns Calculator Online Help. Waters Columns Calculator, version 2.0.
7. Waters Corporation, Application Solutions. Transferring Compendial HPLC Methods to UPLC Technology. Application Notebook. [720004313en](#), 2013.
8. Hong, Paula. McConville, Patricia R. Dwell Volume and Extra-Column Volume: What Are They and How Do They Impact Method Transfer. White Paper. [720005723en](#), 2018.

Waters

THE SCIENCE OF WHAT'S POSSIBLE.™

Waters, The Science of What's Possible, ACQUITY, Alliance, Arc, Empower, UPLC, and XBridge are trademarks of Waters Corporation. All other trademarks are the property of their respective owners.

©2019 Waters Corporation. Produced in the U.S.A. June 2019 720006577EN AG-PDF

Waters Corporation
34 Maple Street
Milford, MA 01757 U.S.A.
T: 1 508 478 2000
F: 1 508 872 1990
www.waters.com